146 related articles for article (PubMed ID: 34254883)
1. Nivolumab in refractory cerebral relapse of Hodgkin's lymphoma.
Lapierre L; Pericart S; Protin C; Borel C; Ysebaert L; Laurent C; Oberic L
Leuk Lymphoma; 2021 Dec; 62(12):3063-3065. PubMed ID: 34254883
[No Abstract] [Full Text] [Related]
2. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
3. Successful brentuximab vedotin and nivolumab therapy of multiply refractory diffuse large B-cell lymphoma with Hodgkin features.
Zibara V; Sen F; Scordo M; Falchi L
Leuk Lymphoma; 2022 Dec; 63(13):3241-3244. PubMed ID: 36120859
[No Abstract] [Full Text] [Related]
4. Brentuximab Vedotin in Advanced Hodgkin's Lymphoma.
Haslam A; Prasad V
N Engl J Med; 2022 Oct; 387(16):1527. PubMed ID: 36260800
[No Abstract] [Full Text] [Related]
5. Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. Reply.
Ansell SM; Radford J; Straus DJ
N Engl J Med; 2022 Oct; 387(16):1527-1528. PubMed ID: 36260801
[No Abstract] [Full Text] [Related]
6. Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma.
Santoro A; Moskowitz AJ; Ferrari S; Carlo-Stella C; Lisano J; Francis S; Wen R; Akyol A; Savage KJ
Blood; 2023 Jun; 141(22):2780-2783. PubMed ID: 36898084
[No Abstract] [Full Text] [Related]
7. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS.
Stefoni V; Marangon M; Re A; Lleshi A; Bonfichi M; Pinto A; Bianchetti N; Pellegrini C; Argnani L; Zinzani PL
Haematologica; 2020 Oct; 105(10):e512. PubMed ID: 33054094
[No Abstract] [Full Text] [Related]
9. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
[TBL] [Abstract][Full Text] [Related]
10. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma.
Castellino SM; Giulino-Roth L; Harker-Murray P; Kahn JM; Forlenza C; Cho S; Hoppe B; Parsons SK; Kelly KM;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30580. PubMed ID: 37505794
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
15. Advances in the treatment of Hodgkin's lymphoma (Review).
Che Y; Ding X; Xu L; Zhao J; Zhang X; Li N; Sun X
Int J Oncol; 2023 May; 62(5):. PubMed ID: 37026506
[TBL] [Abstract][Full Text] [Related]
16. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
[TBL] [Abstract][Full Text] [Related]
17. Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.
Fukuhara N; Yamamoto G; Tsujimura H; Chou T; Shibayama H; Yanai T; Shibuya K; Izutsu K
Leuk Lymphoma; 2020 Jan; 61(1):176-180. PubMed ID: 31437057
[No Abstract] [Full Text] [Related]
18. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
Plattel WJ; Bergamasco A; Trinchese F; Gavini F; Bent-Ennakhil N; Zomas A; Castillon G; Arredondo-Bisono T; Cristarella T; Moride Y; von Tresckow B
Leuk Lymphoma; 2021 Dec; 62(14):3320-3332. PubMed ID: 34323643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]